• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Combined effects of co-stimulatory molecule gene transfer and radiotherapy on immune checkpoint inhibitors

Research Project

  • PDF
Project/Area Number 19H03804
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 56050:Otorhinolaryngology-related
Research InstitutionKobe University

Principal Investigator

Ken-ichi Nibu  神戸大学, 医学研究科, 教授 (20251283)

Co-Investigator(Kenkyū-buntansha) 井之口 豪  神戸大学, 医学部附属病院, 准教授 (10457046)
上原 奈津美  神戸大学, 医学部附属病院, 助教 (40570502)
大月 直樹  神戸大学, 医学研究科, 准教授 (40343264)
Project Period (FY) 2019-04-01 – 2022-03-31
Keywords扁平上皮癌 / 免疫チェックポイント阻害剤 / 共刺激因子 / B7 / CD90
Outline of Final Research Achievements

In our previous study, we reported that gene transfer of the B7 molecule (CD80) into a mouse squamous cell carcinoma model efficiently amplified tumor-specific CTLs and had a growth inhibitory effect not only on tumor cells expressing the B7 molecule (CD 80) but also on non-transfected tumor cells.
In this study, we examined the combined effects of immune checkpoint inhibitors and gene transfer of the co-stimulatory molecule B7 molecule (CD 80) using a mouse squamous cell carcinoma model. The combination of both treatment strategies resulted in almost complete disappearance of tumors transplanted into mice and a significant combined effect.

Free Research Field

耳鼻咽喉科 頭頸部外科

Academic Significance and Societal Importance of the Research Achievements

マウスに移植した扁平上皮がん腫瘍細胞にアデノウイルスベクターを用いて共刺激分子B7(CD80)を導入することにより免疫チェックポイント阻害剤の効果を有意に増強することを示すことができた。免疫チェックポイント阻害剤と共刺激分子の併用という新たな治療法の開発につながる成果が得られた。本治療法が実用化されることが望まれる。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi